Clinical Trials Logo

Cervical Carcinoma clinical trials

View clinical trials related to Cervical Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05824468 Not yet recruiting - Cervical Cancer Clinical Trials

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

Although immune checkpoint inhibitors (ICIs) provide a durable response in multiple tumor types, relapse occurs in most patients with solid tumor. However, the benefits of retreatment with ICIs remains controversial. In some studies, retreatment with ICIs has exhibited encouraging efficacy in patients with solid tumors, particularly in melanoma, and non-small cell lung cancer (NSCLC). In this single arm phase 2 trial, we aimed to evaluate the efficacy and safety of the combination of anti-PD1 antibody (zimberelimab) and lenvatinib in patients with advanced cervical cancer who progressed on or after prior ICIs.

NCT ID: NCT04483557 Not yet recruiting - Cervical Cancer Clinical Trials

Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility

CONTESSA
Start date: September 1, 2020
Phase: Phase 2
Study type: Interventional

The standard treatment of stage Ibl 2-4 cm cervical cancer in women who wish to preserve fertility is an abdominal radical trachelectomy with pelvic lymph node dissection. Since the number of take home babies after completing this procedure is below 10%, there is a need for exploration of alternative treatment modalities with better chances of preserving fertility at equal risk of recurrence. Aim of the study is to assess the feasibility of preserving fertility in women with 2018 FIGO stage IB2 cervical cancer with lesions measuring >2cm - <4cm

NCT ID: NCT03975127 Not yet recruiting - Cervical Carcinoma Clinical Trials

Cervical Cytology - Do SMS Reminders Increase Participation in the Cervical Screening Programme?

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

This study will pilot production and evaluate the use of reminder information in women invited for cervical screening for the first time within the GGC eligible population for cervical screening. Women aged under 30 years will be identified to receive an SMS text message following their cervical screening invitation using information from the CHI Broadcast.

NCT ID: NCT03086681 Not yet recruiting - Cervical Carcinoma Clinical Trials

Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma

ECWHCCFLACC
Start date: March 2017
Phase: Phase 3
Study type: Interventional

A total of 120 patients with pathologically confirmed Locally advanced cervical carcinoma were enrolled. Patients were randomly divided into two groups, with 60 patients in each group. One group was treated with Concurrent Chemoradiotherapy combined with Endostar and the other group was treated with Concurrent Chemoradiotherapy. The short term efficacy and the toxic of these treatments were evaluated. The 1-year, 3-year, 5-year overall survival and progression-free survival of patients were analyzed. The investigators data may provide an alternative option for the treatment of Locally advanced cervical carcinoma with high efficacy and low toxicity.